Avexxin (private company)

See something wrong or missing? Let us know
Offices:Trondheim
Business model:B2B

Avexxin will provide a new generation of therapeutics treating serious medical conditions associated with chronic inflammatory disorders and specific cancers.

Investors: we tracked 3 investors

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to Avexxin

Name Criteria
Norway Vaccibody
53%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one vc investor: Sarsia Seed Management
Norway SonoClear
50%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Sarsia Seed Management
  • At least one other investor: Sparebank 1 SMN Invest
Norway APIM Therapeutics
40%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Sarsia Seed Management
Norway Aristeia
40%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one angel investor: Leiv Eiriksson Nyskaping
Iceland 3Z Pharmaceuticals
38%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
France ABC Transfer
38%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Spain Ability Pharma
38%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
France AbolerIS Pharma
38%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Denmark AFYX Therapeutics
38%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Germany Aignostics
38%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Top